Clinical Trial: Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs
Brief Summary: The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
Detailed Summary: Migraine sufferers undergo vestibular tests and were excluded if there were clinically significant abnormalities. Following screening, there were 2 experimental visits in which migraine sufferers were pre-treated with either Rizatriptan or placebo. After taking the drug, subjects were idle for 2 hours. Baseline motion sickness and subjective units of distress levels were assessed prior to undergoing sinusoidal-earth-vertical earth axis rotation in darkness at 0.05 Hz. Scores were taken immediately after stopping. Subjects were given a 2 minutes rest and then underwent a motion sickness provoking rotation. Subjective scores were assessed immediately following. Another two minute rest was given and if the subject was able, underwent a second motion sickness provoking stimulus followed by an assessment.
Sponsor: University of Pittsburgh
Current Primary Outcome: Change From Baseline in Motion Sickness to Post Vestibular Stimulus [ Time Frame: Pre and Post Stimulus (about 6 minutes apart) ]
Original Primary Outcome: Motion Sickness Scores
Current Secondary Outcome: Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus [ Time Frame: Pre and Post Stimulus (6 minutes apart) ]
Original Secondary Outcome:
Information By: University of Pittsburgh
Dates:
Date Received: August 2, 2006
Date Started: August 2006
Date Completion:
Last Updated: December 4, 2014
Last Verified: December 2014